Proteomic approaches for investigation of therapy resistance in cancer

Proteomics - Clinical Applications

Volumn 3, Issue 8, 2009, Pages 883-911

  Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

Cancer; Drug resistance; Therapy resistance; Therapy response

Indexed keywords

A 204197; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CHOLCICIN; CISPLATIN; COFILIN; COLCHICINE; DAUNORUBICIN; DEHYDRODIDEMNIN B; DEOXYCHOLATE SODIUM; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MELPHALAN; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER TISSUE; CHROMOSOME DELETION; CLINICAL PRACTICE; DOWN REGULATION; ELECTROPHORESIS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SIGNATURE; GENETIC DIFFERENCE; HEAT TOLERANCE; HUMAN; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSCRIPTOMICS; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 70350218728     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800162     Document Type: Review

References (145)

1. Gottesman, M. M., Fojo, T., Bates, S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
2. Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., Gottesman, M. M., Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
3. Lage, H., An overview of cancermultidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65, 3145-3167.
4. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J. et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205-216.
5. Thompson, J. F., Scolyer, R. A., Kefford, R. F., Cutaneous melanoma. Lancet 2005, 365, 687-701.
6. Biedler, J. L., Riehm, H., Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970, 30, 1174-1184.
7. Harari, P. M., Allen, G. W., Bonner, J. A., Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 2007, 25, 4057-4065.
8. Cheson, B. D., Leonard, J. P., Monoclonal antibody therapy for B-cell non-Hodgkins lymphoma. N. Engl. J. Med. 2008, 359, 613-626.
9. Raguz, S., Yag. ue, E., Resistance to chemotherapy: new treatments and novel insights into an old problem. Br. J. Cancer 2008, 99, 387-391.
10. Alaoui-Jamali, M. A., Dupré, I., Qiang, H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist. Updat. 2004, 7, 245-255.
11. Wasinger, V. C., Cordwell, S. J., Cerpa-Poljak, A., Yan, J. X. et al., Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995, 16, 1090-1094.
12. Wilkins, M. R., Sanchez, J. C., Gooley, A. A., Appel, R. D. et al., Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 1996, 13, 19-50.
13. Conrotto, P., Souchelnytskyi, S., Proteomic approaches in biological and medical sciences: principles and applications. Exp. Oncol. 2008, 30, 171-180.
14. Lønning, P. E., Breast cancer prognostication and prediction: are we making progress? Ann. Oncol. 2007, 18, viii3-viii7.
15. Cho, W. C., Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 2007, 5, 77-85.
16. Conrotto, P., Souchelnytskyi, S., Proteomic approaches in biological and medical sciences: principles and applications. Exp. Oncol. 2008, 30, 171-180.
17. Latterich, M., Abramovitz, M., Leyland-Jones, B., Proteomics: new technologies and clinical applications. Eur. J. Cancer 2008, 44, 2737-2741.
18. Panchaud, A., Affolter, M., Moreillon, P., Kussmann, M., Experimental and computational approaches to quantitative proteomics: status quo and outlook. J. Proteomics 2008, 71, 19-33.
19. Wouters, B. G., Proteomics: methodologies and applications in oncology. Semin. Radiat. Oncol. 2008, 18, 115-125.
20. Twentyman, P. R., Fox, N. E., Wright, K. A., Bleehen, N. M., Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br. J. Cancer 1986, 53, 529-537.
21. Takemura, Y., Kobayashi, H., Gibson, W., Kimbell, R. et al., The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Int. J. Cancer 1996, 66, 29-36.
22. Yan, X. D., Pan, L. Y., Yuan, Y., Lang, J. H., Mao, N., Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 2007, 6, 772-780.
23. Tönnies, H., Poland, J., Sinha, P., Lage, H., Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int. J. Cancer 2003, 103, 752-758.
24. Tönnies, H., Lage, H., Chromosomal imbalances associated with drug resistance and thermoresistance in human pancreatic carcinoma cells. Eur. J. Cell Biol. 2004, 83, 591-601.
25. Shen, D. W., Cardarelli, C., Hwang, J., Cornwell, M. et al., Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 1986, 261, 7762-7770.
26. Sinha, P., Poland, J., Schnölzer, M., Celis, J. E., Lage, H., Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis 2001, 22, 2990-3000.
27. Lu, J., Suzuki, T., Satoh, M., Chen, S. et al., Involvement of aldolase A in X-ray resistance of human HeLa and UV(r)-1 cells. Biochem. Biophys. Res. Commun. 2008, 369, 948-952.
28. Besada, V., Diaz, M., Becker, M., Ramos, Y. et al., Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 2006, 6, 1038-1048.
29. Zhang, J. T., Liu, Y., Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat. Rev. 2007, 33, 741-756.
30. Verrills, N. M., Walsh, B. J., Cobon, G. S., Hains, P. G., Kavallaris, M., Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 2003, 278, 45082-45093.
31. Rahbar, A. M., Fenselau, C., Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells. J. Proteome Res. 2005, 4, 2148-2153.
32. Petrak, J., Ivanek, R., Toman, O., Cmejla, R. et al., Déjàvu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8, 1744-1749.
33. Ghosh, M., Song, X., Mouneimne, G., Sidani, M. et al., Cofilin promotes actin polymerization and defines the direction of cell motility. Science 2004, 304, 743-746.
34. Sinha, P., H. utter, G., Köttgen, E., Dietel, M. et al., Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adeno-carcinoma of the pancreas. Electrophoresis 1999, 20, 2952-2960.
35. Strong, R., Nakanishi, T., Ross, D., Fenselau, C., Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. J. Proteome Res. 2006, 5, 2389-2395.
36. Yang, Y. X., Xiao, Z. Q., Chen, Z. C., Zhang, G. Y. et al., Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006, 6, 2009-2021.
37. Hensbergen, P., Alewijnse, A., Kempenaar, J., van der Schors, R. C. et al., Proteomic profiling identifies an UVinduced activation of cofilin-1 and destrin in human epidermis. J. Invest. Dermatol. 2005, 124, 818-824.
38. Thongboonkerd, V., Chutipongtanate, S., Kanlaya, R., Songtawee, N. et al., Proteomic identification of alterations in metabolic enzymes and signaling proteins in hypokalemic nephropathy. Proteomics 2006, 6, 2273-2285.
39. Catterall, J. B., Rowan, A. D., Sarsfield, S., Saklatvala, J. et al., Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatology (Oxford) 2006, 45, 1101-1109.
40. Lee, C. K., Park, H. J., So, H. H., Kim, H. J. et al., Proteomic profiling and identification of cofilin responding to oxidative stress in vascular smooth muscle. Proteomics 2006, 6, 6455-6475.
41. Doll, D., Sarikas, A., Krajcik, R., Zolk, O., Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem. Biophys. Res. Commun. 2007, 353, 436-442.
42. Ciborowski, P., Kadiu, I., Rozek, W., Smith, L. et al., Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007, 363, 198-209.
43. Inberg, A., Bogoch, Y., Bledi, Y., Linial, M., Cellular processes underlying maturation of P19 neurons: changes in protein folding regimen and cytoskeleton organization. Proteomics 2007, 7, 910-920.
44. Donoghue, P., Doran, P., Wynne, K., Pedersen, K. et al., Proteomic profiling of chronic low-frequency stimulated fast muscle. Proteomics 2007, 7, 3417-3430.
45. Pucci-Minafra, I., Cancemi, P., Albanese, N. N., Di Cara, G. et al., New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator. J. Proteome Res. 2008, 7, 1412-1418.
46. Becker, M., Nothwang, H. G., Friauf, E., Different protein profiles in inferior colliculus and cerebellum: A comparative proteomic study. Neuroscience 2008, 154, 233-244.
47. Sinha, P., Poland, J., Kohl, S., Schnölzer, M. et al., Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 2003, 24, 2386-2404.
48. Poland, J., Urbani, A., Lage, H., Schnölzer, M., Sinha, P., Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis 2004, 25, 173-183.
49. Urbani, A., Poland, J., Bernardini, S., Bellincampi, L. et al., A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005, 5, 796-804.
50. Liu, Y., Liu, H., Han, B., Zhang, J. T., Identification of 14-3-3 sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 2006, 66, 3248-3255.
51. Verrills, N. M., Liem, N. L., Liaw, T. Y., Hood, B. D. et al., Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study. Proteomics 2006, 6, 1681-1694.
52. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K. et al., Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 2007, 31, 1345-1350.
53. Lage, H., Proteomics in cancer cell research: an analysis of therapy resistance. Pathol. Res. Pract. 2004, 200, 105-117.
54. Ehrnsperger, M., Graber, S., Gaestel, M., Buchner, J., Binding of non-native protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. EMBO J. 1997, 16, 221-229.
55. Lavoie, J. N., Gingras-Breton, G., Tanguay, R. M., Landry, J., Induction of Chinese hamster HSP27 gene expression in mouse cells confers resistance to heat shock. HSP27 stabilization of the microfilament organization. J. Biol. Chem. 1993, 268, 3420-3429.
56. Fortin, A., Raybaud-Diogene, H., Tetu, B., Deschenes, R. et al., Overexpression of the 27 kDa heat shock protein is associated with thermoresistance and chemoresistance but not with radioresistance. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46, 1259-1266.
57. Luk, J. M., Lam, C. T., Siu, A. F., Lam, B. Y. et al., Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) upregulation and their associated prognostic values. Proteomics 2006, 6, 1049-1057.
58. Matt, P., Fu, Z., Carrel, T., Huso, D. L. et al., Proteomic alterations in heat shock protein 27 and identification of phosphoproteins in ascending aortic aneurysm associated with bicuspid and tricuspid aortic valve. J. Mol. Cell. Cardiol. 2007, 43, 792-801.
59. Fu, H., Subramanian, R. R., Masters, S. C., 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 617-647.
60. Monge, M., Vilaseca, M., Soto-Cerrato, V., Montaner, B. et al., Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line. Invest. New Drugs 2007, 25, 21-29.
61. Hermeking, H., Lengauer, C., Polyak, K., He, T. C. et al., 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1997, 1, 3-11.
62. Chan, T. A., Hermeking, H., Lengauer C., Kinzler, K. W., Vogelstein, B., 14-3-3s is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401, 616-620.
63. Yang, H. Y., Wen, Y. Y., Chen, C. H., Lozano, G., Lee, M. H., 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 2003, 23, 7096-7107.
64. Voss, T., Ahorn, H., Haberl, P., Döhner, H., Wilgenbus, K., Correlation of clinical data withproteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int. J. Cancer 2001, 91, 180-186.
65. Verrills, N. M., Po'uha, S. T., Liu, M. L., Liaw, T. Y. et al., Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J. Natl. Cancer Inst. 2006, 98, 1363-1374.
66. Marie, J. P., Zhou, D. C., Gurbuxani, S., Legrand, O., Zittoun, R., MDR1/ P-glycoprotein in haematological neoplasms. Eur. J. Cancer 1996, 32A, 1034-1038.
67. Orr, G. A., Verdier-Pinard, P., McDaid, H., Horwitz, S. B., Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22, 7280-7295.
68. Ong, V., Liem, N. L., Schmid, M. A., Verrills, N. M. et al., Mackenzie, K.L., Kavallaris, M., Lock, R.B., A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J. Pharmacol. Exp. Ther. 2008, 324, 434-442.
69. Allal, A. S., K.ahne, T., Reverdin, A. K., Lippert, H. et al., Radioresistance-related proteins in rectal cancer. Proteomics 2004, 4, 2261-2269.
70. Gehrmann, M. L., Hathout, Y., Fenselau, C., Evaluation of metabolic labeling for comparative proteomics in breast cancer cells. J. Proteome Res. 2004, 3, 1063-1068.
71. Gehrmann, M. L., Fenselau, C., Hathout, Y., Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J. Proteome Res. 2004, 3, 403-409.
72. Okano, T., Kondo, T., Fujii, K., Nishimura, T. et al., Proteomic signature corresponding to the response to gefitinib (iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin. Cancer Res. 2007, 13, 799-805.
73. Brown, M. P., Grundy, W. N., Lin, D., Cristianini, N. et al., Knowledge based analysis of microarray gene expression data by using support vector machines. Proc. Natl. Acad. Sci. USA 2000, 97, 262-267.
74. Poland, J., Schadendorf, D., Lage, H., Schnölzer, M. et al., Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 2002, 40, 221-234.
75. Skvortsov, S., Sarg, B., Loeffler-Ragg, J., Skvortsova, I. et al., Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol. Cancer Ther. 2004, 3, 1551-1558.
76. Taguchi, F., Solomon, B., Gregorc, V., Roder, H. et al., Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl. Cancer Inst. 2007, 99, 838-846.
77. Webb, A., Statistical Pattern Recognition, Chichester (UK), Wiley 2002.
78. Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A. G. et al., Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000, 60, 4161-4166.
79. Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T. et al., Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum. Cell 2001, 14, 305-315.
80. Xia, L., Zhang, D., Du, R., Pan, Y. et al., miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123, 372-379.
81. Györffy, B., Serra, V., J. urchott, K., Abdul-Ghani, R. et al., Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005, 24, 7542-7551.
82. Minna, J. D., Girard, L., Xie, Y., Tumor mRNA expression profiles predict responses to chemotherapy. J. Clin. Oncol. 2007, 25, 4329-4336.
83. Györffy, B., Surowiak, P., Kiesslich, O., Denkert, C. et al., Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 2006, 118, 1699-1712.
84. Györffy, B., Serra, V., Materna, V., Sch. afer, R. et al., Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Res. 2006, 16, 147-155.
85. Thuerigen, O., Schneeweiss, A., Toedt, G., Warnat, P. et al., Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 2006, 24, 1839-1845.
86. Del Rio, M., Molina, F., Bascoul-Mollevi, C., Copois, V. et al., Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 2007, 25, 773-780.
87. Dressman, H. K., Berchuck, A., Chan, G., Zhai, J. et al., An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 2007, 25, 517-525.
88. Denkert, C., Budczies, J., Darb-Esfahani, S., Györffy, B. et al., A prognostic gene expression index in ovarian cancer: validation across different independent datasets. J. Pathol. 2009, 218, 273-280.
89. Györffy, B., Lage, H., A Web-based data warehouse on gene expression in human malignant melanoma. J. Invest. Dermatol. 2007, 127, 394-399.
90. Györffy, B., Dietel, M., Fekete, T., Lage, H., A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int. J. Gynecol. Cancer 2008, 18, 1215-1233.
91. Chen, G., Gharib, T. G., Huang, C. C., Taylor, J. M. et al., Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 2002, 1, 304-313.
92. Sagynaliev, E., Steinert, R., Nestler, G., Lippert, H. et al., Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 2005, 5, 3066-3078.
93. van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D. et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
94. Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobágyi, G. N., Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13, 477-493.
95. Butcher, E., Berg, E. L., Kunkel, E. J., Systems biology in drug discovery. Nat. Biotechnol. 2004, 22, 1253-1259.
96. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
97. Mischak, H., Apweiler, R., Banks, R. E., Conaway, M. et al., Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
98. Hathout, Y., Riordan, K., Gehrmann, M., Fenselau, C., Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. J. Proteome Res. 2002, 1, 435-442.
99. Sinha, P., Kohl, S., Fischer, J., H. utter, G. et al., Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using twodimensional electrophoresis. Electrophoresis 2000, 21, 3048-3057.
100. Sinha, P., H. utter, G., Köttgen, E., Dietel, M. et al., Increased expression of annexin I and thioredoxin detected by twodimensional gel electrophoresis of drug resistant human stomach cancer cells. J. Biochem. Biophys. Methods 1998, 37, 105-116.
101. Sinha, P., H. utter, G., Köttgen, E., Dietel, M. et al., Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 1999, 20, 2961-2969.
102. Keenan, J., Murphy, L., Henry, M., Meleady, P., Clynes, M., Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 2009, 9, 1556-1566.
103. Eriksson, H., Lengqvist, J., Hedlund, J., Uhlén, K. et al., Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 2008, 8, 3008-3018.
104. Qi, J., Liu, N., Zhou, Y., Tan, Y. et al., Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem. Biophys. Res. Commun. 2006, 349, 303-309.
105. Shen, S. H., Gu, L. J., Liu, P. Q., Ye, X. et al., Comparative proteomic analysis of differentially expressed proteins between K562 and K562/ADM cells. Chin. Med. J. 2008, 121, 463-468.
106. Chuthapisith, S., Layfield, R., Kerr, I. D., Hughes, C., Eremin, O., Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int. J. Oncol. 2007, 30, 1545-1551.
107. Mian, S., Ball, G., Hornbuckle, J., Holding, F. et al., A prototype methodology combining surface-enhanced laser desorption/ ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to paclitaxel and doxorubicin under in vitro conditions. Proteomics 2003, 3, 1725-1737.
108. Brown, K. J., Fenselau, C., Investigation of doxorubicin resistance in MCF-7 breast cancer cells using shot-gun comparative proteomics with proteolytic 18O labeling. J. Proteome Res. 2004, 3, 455-462.
109. Fu, Z., Fenselau, C., Proteomic evidence for roles for nucleolin and poly ADP-ribosyl transferase in drug resistance. J. Proteome Res. 2005, 4, 1583-1591.
110. Smith, L., Watson, M. B., O'Kane, S. L., Drew, P. J. et al., The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 2006, 5, 2115-2120.
111. Yang, Y. X., Hu, H. D., Zhang, D. Z., Ren, H., Identification of proteins responsible for the development of adriamycin resistance in human gastric cancer cells using comparative proteomics analysis. J. Biochem. Mol. Biol. 2007, 40, 853-860.
112. Huber, M., Bahr, I., Kr.atzschmar, J. R., Becker, A. et al., Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogenresistant derivative T47D-r. Mol. Cell. Proteomics 2004, 3, 43-55.
113. Murphy, L., Clynes, M., Keenan, J., Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma. Anticancer Res. 2007, 27, 1277-1284.
114. Liu, F., Chen, Z., Wang, J., Shao, X. et al., Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 2008, 10, 1275-1284.
115. Castagna, A., Antonioli, P., Astner, H., Hamdan, M. et al., A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4, 3246-3267.
116. Shen, D. W., Akiyama, S., Schoenlein, P., Pastan, I., Gottesman, M. M., Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br. J. Cancer 1995, 71, 676-683.
117. Stewart, J. J., White, J. T., Yan, X., Collins, S. et al., Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 2006, 5, 433-443.
118. Le Moguen, K., Lincet, H., Deslandes, E., Hubert-Roux, M. et al., Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006, 6, 5183-5192.
119. Le Moguen, K., Lincet, H., Marcelo, P., Lemoisson, E. et al., A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Proteomics 2007, 7, 4090-4101.
120. Smith, L., Welham, K. J., Watson, M. B., Drew, P. J. et al., The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol. Res. 2007, 16, 497-506.
121. Yoo, B. C., Ku, J. L., Hong, S. H., Shin, Y. K. et al., Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int. J. Cancer 2004, 108, 532-539.
122. Murphy, L., Henry, M., Meleady, P., Clynes, M., Keenan, J., Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim. Biophys. Acta 2008, 1784, 1184-1191.
123. Tanaka, S., Sakai, A., Kimura, K., Yoshida, H. et al., Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis. Int. J. Oncol. 2008, 33, 361-370.
124. Yoo, B. C., Jeon, E., Hong, S. H., Shin, Y. K. et al., Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. Clin. Cancer Res. 2004, 10, 4176-4184.
125. Shin, Y. K., Yoo, B. C., Chang, H. J., Jeon, E. et al., Downregulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 2005, 65, 3162-3170.
126. Choong, L. Y., Lim, S., Loh, M. C., Man, X. et al., Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in targetdirected therapeutics. Mol. Cancer Ther. 2007, 6, 2828-2842.
127. Pocaly, M., Lagarde, V., Etienne, G., Dupouy, M. et al., Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics 2008, 8, 2394-2406.
128. Rosenhahn, J., Weise, A., Michel, S., Hennig, K. et al., Cytogenetic characterisation and proteomic profiling of the imatinib-resistant cell line KCL22-R. Int. J. Oncol. 2007, 31, 121-128.
129. Ferrari, G., Pastorelli, R., Buchi, F., Spinelli, E. et al., Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J. Proteome Res. 2007, 6, 367-375.
130. Vazquez-Martin, A., Oliveras-Ferraros, C., Colomer, R., Brunet, J., Menendez, J. A., Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann. Oncol. 2008, 19, 1097-1109.
131. Kuang, Y. H., Chen, X., Su, J., Wu, L. S. et al., Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J. Proteome Res. 2008, 7, 4784-4791.
132. Peng, S. F., Fu, L., Tan, D. M., Heat-shock protein 27 linked to multi-drug resistance in human hepatic cancer cell lines Article in Chinese. Zhonghua Gan Zang Bing Za Zhi 2007, 15, 362-365.
133. Yi, H., Yang, Y. X., Tang, C. E., Chen, Z. C. et al., Sorcin overexpression and multidrug resistance in human gastric cancer cells Article in Chinese. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31, 340-349.
134. Yang, Y. X., Chen, Z. C., Zhang, G. Y., Yi, H., Xiao, Z. Q., A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J. Cell Biochem. 2008, 104, 1010-1021.
135. Wang, X., Lu, Y., Yang, J., Shi, Y. et al., Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis. J. Cancer Res. Clin. Oncol. 2008, 134, 995-1003.
136. Han, E. K., Tahir, S. K., Cherian, S. P., Collins, N., Ng, S. C., Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer 2000, 83, 83-88.
137. González-Santiago, L., Alfonso, P., Suárez, Y., Núñez, A. et al., Proteomic analysis of the resistance to aplidin in human cancer cells. J. Proteome Res. 2007, 6, 1286-1294.
138. Bernstein, H., Payne, C. M., Kunke, K., Crowley-Weber, C. L. et al., A proteomic study of resistance to deoxycholateinduced apoptosis. Carcinogenesis 2004, 25, 681-692.
139. Nishizuka, S., Charboneau, L., Young, L., Major, S. et al., Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 2003, 100, 14229-14234.
140. Ma, Y., Ding, Z., Qian, Y., Shi, X. et al., Predicting cancer drug response by proteomic profiling. Clin. Cancer Res. 2006, 12, 4583-4589.
141. Wang, T., Tamae, D., LeBon, T., Shively, J. E. et al., The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 2005, 65, 10338-10346.
142. Lacroix, M., Persistent use of "false" cell lines. Int. J. Cancer 2008, 122, 1-4.
143. Liscovitch, M., Ravid, D., A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 2007, 245, 350-352.
144. Iwadate, Y., Sakaida, T., Saegusa, T., Hiwasa, T. et al., Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int. J. Oncol. 2005, 26, 993-998.
145. Lage, H., Molecular analysis of therapy resistance in gastric cancer. Dig. Dis. 2003, 21, 326-338.